Exercise regularly
Who Should NOT Consider Peptides Based on current evidence, I would advise against peptide use in the following individuals: Anyone with a current or recent cancer diagnosis Anyone with a strong family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate, colorectal) Anyone with genetic mutations predisposing to cancer (BRCA1/2, Lynch syndrome, etc.) Anyone with active autoimmune disease or severe inflammatory conditions Pregnant or breastfeeding women Anyone who has not established foundational health practices Competitive athletes (most peptides are banned substances) Anyone seeking a "quick fix" rather than commitment to comprehensive health optimization If Considering Peptides: A Cautious Approach For patients who have established solid foundations, have no contraindications, understand the limitations of current evidence, and wish to explore peptides as a potential adjunct, here is the approach I might considerwith significant caveats: Lower-Risk Starting Point Topical GHK-Cu: This has the most established safety profile and documented benefits for skin health
Many of these variations arise from genetic differences in hormone programming or metabolism
In the hypothetical alliin biosynthetic pathway, two different routes from the intermediate -glutamyl- S -allyl-L-cysteine to alliin are possible, according to differences in the order of deglutamylation and S -oxygenation reactions ( Figure 1 ): a potential route via deglutamylation of -glutamyl- S -allyl-L-cysteine to yield S -allyl-L-cysteine that is further S -oxygenated to alliin, and an alternative route via S -oxygenation of -glutamyl- S -allyl-L-cysteine to form -glutamyl- S -allyl-L-cysteine sulfoxide that is further deglutamylated to yield alliin
The highly anticipated results are expected to readout in September 2025 9
